The use of metformin (Siofora®) in patients with abdominal type of obesity
https://doi.org/10.14341/probl11873
Abstract
The aim of this study was to compare the efficiency of various methods of treating patients with abdominal obesity and dyslipidemia at the stage ofpreclinical manifestation of cardiovascular complications. One group (13 pts) was treated by diets, the other (19 pts) by diet and metmorphine in a daily dose of 1000 mg. The duration of study was 6 months. Anthropometric, biochemical, and hormonal values were checked up in all patients at the beginning and end of therapy and in some patients after 3 months of treatment. The results indicate that metmorphine in combination with traditional therapy is a rational treatment affecting various factors determining the summary risk of cardiovascular diseases in patients with abdominal obesity.
About the Authors
I. I. DedovEndocrinology Research Center RAMS
Russian Federation
S. A. Butrova
Endocrinology Research Center RAMS
Russian Federation
B. P. Mishchenko
Endocrinology Research Center RAMS
Russian Federation
F. Kh. Dzgoeva
Endocrinology Research Center RAMS
Russian Federation
References
1. Демидова И., Игнатова Н., Рейдис И. // Клин, эндокринол. 1998. № 1. С. 3-27.
2. Старостина Е. // Новый мед. журн. — 1998. — № 1. — С. 3-11.
3. Assmann G., Cullen Р., Schulte Н. // Eur. Heart J. — 1998. — Vol. 19. Suppl. A. P. 3-11.
4. Avignon A., Baegner C., Mariano-Goulart D. et al. // Int. J. Obesity. 1999. Vol. 23. P. 512-517.
5. Brochier M., Arwidson P. // Eur. Heart J. — 1998. — Vol. 19. — Suppl. A. — P. 45—52.
6. Caro J. // J. Clin. Endocrinol. — 1991. — Vol. 73, N 4. — P. 691-696.
7. Crave J., Fimbel S. et al. // Ibid. — 1995. — Vol. 80. — P. 2057-2069.
8. De Fronzo R., Barziliai N., Simonson D. // Ibid. — 1991. — Vol. 73. P. 1294-1301.
9. Despres J., Moorjanni, Lupien P. et al. // Arteriosclerosis. — 1990. Vol. 10. N 4. P. 497-511.
10. Fendri S.. Debussche X., Pue H. et al. // Deabete and Metab.1993. Vol. 19. P. 245-249.
11. Ferrannini E. // Metabolism. — 1995. — Vol. 44, N 9. — Suppl. 3. P. 15-17.
12. Friedwald W. T., Levy R. J., Fredrickson D. S. // Clin. Chem.1972. Vol. 18. P. 499-502.
13. Gensini G., Comeglio M., Colella A. // Eur. Heart J. — 1998. — Vol. 19. — Suppl. A. — P. 53—61.
14. Giugliano D., De Rosa N. et al. // Diabetes Care. — 1993. — Vol. 16, N 9. P. 1387-1390.
15. Hanefeld M., Leonhardt W. Das Metabolische Syndrome. — Dresden, 1996.
16. Jahan-Vague L, Alessi M. C. // Thrombos. and Haemostas. — 1997. Vol. 78, N 1. P. 656-660.
17. Kissebah A. // Diabetes Rev. — 1997. — Vol. 5, N 1. — P. 8— 20.
18. Nestler J. E. et al. // J. Clin. Endocrinol. — 1994. — Vol. 78.P. 549-554.
19. Pentikainen P., Voutilainen E., Aro A. et al. // Ann. Med. — 1990. Vol. 22. P. 307-312.
20. Perriello G., Misericordia P.. Volpi E. et al. // Diabetes. — Vol. 43. P. 920-928.
21. Reaven G. M. // Ibid. 1988. Vol. 37. P. 1595-1601.
22. Vague P., Rindnichi A. et al. // Abstract of 30-th Annual Meeting of European Association for the Study of Dcabetes. — Diisseldorf, 1994. — P. 62.
23. Wood D.. Backer G. et al. Together with members of the Task Force, Prevention of Coronary Heart Disease in Clinical Practice (Summary of the recommendation of the Second Joint Task Force of the Joint European and other Societes on Coronary Prevention). — Atherosclerosis, 1998.
Review
For citations:
Dedov I.I., Butrova S.A., Mishchenko B.P., Dzgoeva F.Kh. The use of metformin (Siofora®) in patients with abdominal type of obesity. Problems of Endocrinology. 2000;46(5):25-29. (In Russ.) https://doi.org/10.14341/probl11873
Views:
21116
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
